#MicroRNA: Enhancing cancer response to radiation

Google+ Pinterest LinkedIn Tumblr +

hastag twitter concept_oncology news australiaResearcher Sudarshan Anand has a contemporary analogy to describe microRNA: “I sometimes compare MicroRNA to tweets—they’re short, transient and constantly changing.”

Because microRNA is dynamic, it makes for a compelling target for cancer research.

Anand, an assistant professor of radiation medicine in the School of Medicine, Oregon Health & Science University, and member of the Knight Cancer Institute, teamed up with a group of researchers to take a closer look at microRNA in the context of the tumour microenvironment.

Their findings, published in Nature Communications, provide early evidence that a panel of microRNA may be used in the future as a biomarker for several types of cancer.

Using a mouse model, Anand and colleagues demonstrated how microRNAs in the tumour microenvironment play a critical role in tumour progression and response to radiation therapy. With microRNAs, the team mimicked features of the autoimmune disease lupus within cancers to provoke an immune response.

hashtag studyenhanci

Researchers Cristina Espinosa, Rebecca Ruhl and Sudarshan Anand in the lab. Credit: OHSU

This promising, early research may one day translate to human cancer radiation and treatment, and begs the question: Can we use microRNA biomarkers to influence cancer radiation? Anand and team believe it is a line of inquiry worth pursuing.

“Biology is such a random process,” Anand says. “Two neighboring cells won’t always act the same way, just like two people don’t react the same way when they see the same event. We hope we will one day be able to read microRNAs and predict if a person’s cancer is going to respond to radiation.”
[hr] SourceOregon Health & Science University 

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.